Castle Biosciences Reports Q3 Revenue Beat and Raises FY2026 Guidance
Castle Biosciences (CSTL) reported third-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted revenue of $102.9 million, representing a 24% year-over-year increase and beating estimates by approximately $10 million. Non-GAAP earnings per share (EPS) came in at -$0.13, which was $0.22 better than anticipated. Driven by strong performance, the company raised its full-year 2026 revenue guidance to a range of $385 million to $395 million. While the net loss widened to $4.1 million due to non-cash stock-based compensation, Adjusted EBITDA saw significant growth, increasing 38% year-over-year to $12.7 million. Management maintained its outlook for positive Adjusted EBITDA in Q4 2026 and throughout 2027.
Tickers: $CSTL
Topics: adjusted ebitda earnings beat guidance raise revenue growth